Depomed’s ProQuin XR is exclusively licensed to Rottapharm|Madaus for Europe and is a once-daily extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections.
Antonino Santoro, corporate business development and regulatory affairs director of Rottapharm|Madaus, said: “ProQuin XR complements our product portfolio and strengthens our position in urology. ProQuin XR’s approval in Sweden paves the way for further regulatory approvals in other European countries through the mutual recognition procedure.
“We expect to launch the product under the trade-mark Utiminx starting in 2009 in different countries and in some of them we are planning to co-market the product under the secondary trade-mark Uritent.”